79878-02-7

Usage

Uses

Used in Pharmaceutical and Chemical Industries:
1-(6-bromo-1H-indol-3-yl)-2,2,2-trifluoroethanone is used as a building block for the preparation of various pharmaceuticals and bioactive molecules. Its structural diversity and potential for further functionalization make it a valuable compound in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(6-bromo-1H-indol-3-yl)-2,2,2-trifluoroethanone is used as a key intermediate for the synthesis of complex organic molecules. Its unique structure allows for a wide range of reactions and transformations, facilitating the creation of novel compounds with potential applications in various industries.
Used in Medicinal Chemistry:
1-(6-bromo-1H-indol-3-yl)-2,2,2-trifluoroethanone is used as a starting material for the development of new drugs and therapeutic agents. Its potential biological activities, including anticancer and anti-inflammatory properties, make it an attractive candidate for further research and development in medicinal chemistry.
Used in Research and Development:
Due to its unique structure and potential biological activities, 1-(6-bromo-1H-indol-3-yl)-2,2,2-trifluoroethanone is used as a valuable target for research and development in the pharmaceutical and chemical industries. Its study can lead to the discovery of new compounds with improved properties and applications in various fields, such as drug discovery, material science, and chemical engineering.

Upstream product

• 16732-65-3 6-bromo-indole-2-carboxylic acid(Ref_.7.) 
• 76-05-1 trifluoroacetic acid 
• 52415-29-9 6-bromo-1H-indole 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 868656-97-7 6-bromo-1H-indole-3-carboxylic acid methyl ester 
• 1296199-36-4 N-(3-methoxybenzyl)-6-(pyridin-4-yl)-1H-indole-3-carboxamide 
• 1296202-22-6 C₂₃H₁₉BrN₂O₂ 
• 1350725-62-0 C₁₆H₉BrF₃NO 
• 1296199-77-3 N-(2-(dimethylamino)ethyl)-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1-(2-(pyrrolidin-1-yl)ethyl)-1H-indole-3-carboxamide 
• 1296199-54-6 1-(2-(dimethylamino)ethyl)-N-(3-methoxybenzyl)-N-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 
• 1296199-53-5 SR₆₇₈₁ 
• 1296199-56-8 1-(3-hydroxypropyl)-N-(3-methoxybenzyl)-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 
• 1296199-69-3 N-(2-(dimethylamino)ethyl)-N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 
• 1296199-70-6 N-(3-(dimethylamino)propyl)-N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 
• 1296199-81-9 N-(3-methoxybenzyl)-1-phenyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 
• 1296199-67-1 N-(3-methoxybenzyl)-N,1-dimethyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 
• 1296199-66-0 N-(3-methoxybenzyl)-1-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 
• 1296199-40-0 N-(3-methoxybenzyl)-N-methyl-6-(1H-pyrazol-4-yl)-1H-indole-3-carboxamide 

Relevant academic research and scientific papers

Total synthesis and biological studies of TMC-205 and analogues as anticancer agents and activators of SV40 promoter

TMC-205 is a natural fungal metabolite with antiproliferative activity against cancer cell lines. The light- and air-sensitivity prevented in-depth exploitation of this novel indole derivative. Herein, we report the first synthesis of TMC-205. On the basi

A simple and efficient total synthesis of anticancer indole alkaloids TMC-205 and its analogues

A concise synthesis of TMC-205 was accomplished in two steps via a protecting-group-free (PGF) and redox-economical strategy. In this approach, a high yield Pinnick oxidation and a practical Heck-dehydration reaction with high atom economy as well as a high regio- and stereo-selectivity (E-isomer) were used and further applied to the total synthesis of its active analogues. This newly established route would be beneficial for future structure–activity relationship (SAR) and biological studies. The synthetic strategy and methodologies demonstrated in this paper could be extended to related biologically active natural products.

REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS

The present disclosure provides compounds of Formula IA and Formula IB and their pharmaceutical compositions as selective agonists of REV-ERB-α: where R1, R2, R3, R4, R5, RX1, RX2, nA, nB, X, Y, and Z are described herein. The compounds are useful in various methods and uses, such as in the treatment of diseases including hyperglycemia, dyslipidemia, atherosclerosis, and autoimmune and inflammatory disorders or diseases, and as cancer therapeutics, such as for the treatment of glioblastoma, hepatocellular carcinoma, and colorectal cancer, and for immune-oncology purposes.

PHOSPHONATE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS

Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula (I), or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is a phosphonate substituent (R32) are provided. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

AROMATIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS

Provided herein are novel aromatic heterocyclic compounds or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and their uses for treating Alzheimer's disease. Also provided herein are pharmaceutical compositions containing such compounds, and methods for using such compounds or pharmaceutical compositions thereof to treat Alzheimer's disease.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

8 - SUBSTITUTED 2 -AMINO - [1,2,4] TRIAZOLO [1, 5 -A] PYRAZINES AS SYK TRYROSINE KINASE INHIBITORS AND GCN2 SERIN KINASE INHIBITORS

Compounds of the formula I in which R1, R2 and R4 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus

NOVEL BIS-INDOLIC DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG

The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

BIS-INDOLIC DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG

The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

BICYCLIC HETEROARYLS AS KINASE INHIBITORS

The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.